+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Stimulation of Eryptosis by Caspofungin



Stimulation of Eryptosis by Caspofungin



Cellular Physiology and Biochemistry 39(3): 939-949



The echinocandin antifungal agent caspofungin has been shown to trigger apoptosis of fungal cells. Beyond that, caspofungin is toxic for host mitochondria. Even though lacking mitochondria, erythrocytes may enter apoptosis-like suicidal erythrocyte death or eryptosis, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Signaling involved in triggering of eryptosis include increase of cytosolic Ca2+ activity ([Ca2+]i), oxidative stress, ceramide, caspase activation and/or activation of p38 kinase, protein kinase C, and casein kinase. The present study explored, whether caspofungin induces eryptosis and, if so, to shed some light on the cellular mechanisms involved. Flow cytometry was employed to determine phosphatidylserine exposure at the cell surface from annexin-V-binding, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, ROS formation from DCFDA dependent fluorescence, and ceramide abundance utilizing specific antibodies. Hemolysis was quantified from hemoglobin concentration in the supernatant. A 48 hours exposure of human erythrocytes to caspofungin (≥ 30 µg/ml) significantly increased the percentage of annexin-V-binding cells, significantly decreased forward scatter, significantly enhanced hemolysis, but did not significantly increase Fluo3-fluorescence, DCFDA fluorescence or ceramide abundance. The effect of caspofungin on annexin-V-binding was not significantly blunted by removal of extracellular Ca2+, by inhibition of caspases with pancaspase inhibitor zVAD (10 µM), or by addition of the antioxidant N-acetyl-cysteine (1 mM), p38 kinase inhibitor SB203580 (2 µM) or protein kinase C inhibitor staurosporine (1 µM). The effect of caspofungin on annexin-V-binding was, however, significantly blunted in the presence of casein kinase inhibitor D4476 (10 µM). Caspofungin triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect possibly involving activation of casein kinase.

(PDF emailed within 0-6 h: $19.90)

Accession: 058905845

Download citation: RISBibTeXText

PMID: 27513568

DOI: 10.1159/000447802


Related references

Stimulation of Eryptosis by Narasin. Cellular Physiology and Biochemistry 37(5): 1807-1816, 2016

Stimulation of Eryptosis by Afatinib. Cellular Physiology and Biochemistry 47(3): 1259-1273, 2018

Stimulation of eryptosis by cryptotanshinone. Cellular Physiology and Biochemistry 34(2): 432-442, 2015

Stimulation of eryptosis by aluminium ions. Toxicology and Applied Pharmacology 217(2): 168-175, 2006

Stimulation of eryptosis by anti-A IgG antibodies. Cellular Physiology and Biochemistry 20(5): 591-600, 2007

Stimulation of eryptosis by cadmium ions. Cellular Physiology and Biochemistry 22(1-4): 245-252, 2008

Sulindac sulfide--induced stimulation of eryptosis. Cellular Physiology and Biochemistry 30(4): 1072-1082, 2013

Stimulation of Eryptosis, the Suicidal Erythrocyte Death by Piceatannol. Cellular Physiology and Biochemistry 38(6): 2300-2310, 2017

Stimulation of Eryptosis by Combretastatin A4 Phosphate Disodium (CA4P). Cellular Physiology and Biochemistry 38(3): 969-981, 2016

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Journal of Infection 50(3): 196-205, 2005

Efficacies of caspofungin and a combination of caspofungin and meropenem in the treatment of murine disseminated candidiasis. Apmis 114(12): 829-836, 2007

Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. Journal of Antimicrobial ChemoTherapy 62(5): 1094-1100, 2008

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. Journal of Antimicrobial ChemoTherapy 53(5): 878-881, 2004

Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum. Mycopathologia 178(3-4): 197-206, 2015

Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrobial Agents and ChemoTherapy 54(5): 1864-1871, 2010